Facts & Figures
Since our foundation in 1993, we have offered investors direct access to a select portfolio of promising, fast growing and profitable biotech companies listed on stock markets around the world. Thanks to our strong track record over the years and our systematic strategy and clear focus, we have become one of the world’s largest biotech investors.
Biotechnology is one of the most attractive of any sector today with estimated annual growth in the double-digits. Mega trends such as increasing life expectancy and a Westernized diet and lifestyle are powerful growth drivers. These mega trends have led to a tremendous increase in healthcare costs, which, in turn, only amplifies the need for more efficient and effective drugs.
Furthermore, many pharmaceutical giants are confronted with deep cuts in revenue streams as a result of patent expirations. They are now purchasing innovative biotech products in an attempt to replenish product pipelines and have been willing to pay top dollar in these deals.
Meanwhile every second drug approved today stems from the labs of a biotech company and many biotech firms have been reporting strong sales and profit growth. The biotech industry has obviously come of age and reached a certain level of maturity.
|SIX Swiss Exchange||Value||YTD||since Nov. 1993*|
|Net Asset Value (NAV)||CHF 57.35||10.8%||1738.0%|
|Deutsche Börse||Value||YTD||since Dec. 1997*|
|Net Asset Value (NAV)||EUR 52.45||8.1%||1358.8%|
|Borsa Italiana||Value||YTD||since Oct. 2000*|
|Net Asset Value (NAV)||EUR 52.45||8.1%||236.7%|
Facts & Figures
November 9, 1993,
Issue price adj.
Switzerland: December 27, 1993
CHF 11.08 mn nominal, 55'400'000 registered shares with a par value of CHF 0.2
Shareholders, free float as at 31/12/16
Institutional and private investors
100% free float
Security number Switzerland
3 838 999
Security number Germany and Italy
Switzerland: BION SW
|Type / asset class||Investment trust / equity|
|Investment approach||Long only, long term|
|Index membership||Stoxx Europe 600, Star Index|
|Benchmark||Nasdaq Biotech Index (NBI)|
|Management Fee||All-in-Fee: 1.1% p.a.|
Market capitalization at the end of the period (in CHF mn)
Net Asset Value at the end of the period (in CHF mn)
Number of shares (in mn) 1
Trading volume (in CHF mn)
Profit/(loss) in CHF mn
Closing price at the end of the period in CHF 1
Closing price (G) at the end of the period in EUR 1
Closing price (I) at the end of the period in EUR 1
Stock performance (inc. distributions)
High/low share price in CHF 1
High/low share price in EUR1
Premium/(Discount) (annual average)
Cash distribution/dividend in CHF (*proposal) 1
Degree of investment (quarterly figures)
Total Expense Ratio (TER) p.a.
1) The five-for-one share split as at March 29, 2016 is accounted for in the previous year's values.
|Deutsche Bank||Gunnar Romer, Falko Friedrichs|
|Oddo Seydler||Igor Kim|
|Equita||Martino De Ambroggi|
|Edison||Sarah Godfrey, Andrew Mitchell|
|Cantor Fitzgerald||Charles Tan|